ElizabethConnickMD

Infectious Disease • Tucson, AZ

Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Dr. Connick is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Connick's full profile

Already have an account?

Office
1501 N Campbell Ave
Tucson, AZ 85724
Phone+1 520-694-0111

Fax+1 520-694-4085

Education & Training

University of ColoradoFellowship, Infectious Disease, 1991 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1988 - 1991
Harvard Medical SchoolClass of 1988

Certifications & Licensure

AZ State Medical License 2016 - 2026
CO State Medical License 1992 - 2017
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV Start of enrollment: 1999 May 01
Completed
Phase 2
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
Withdrawn
Phase 2

Publications & Presentations

PubMed

7 citations
Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control.
Adam Wedrychowski, Holly Anne Martin, Yijia Li, Sushama Telwatte, Gayatri Nikhila Kadiyala
Journal of Virology. 2023-01-31
15 citations
Antiretroviral Therapy and Vaginally Administered Contraceptive Hormones: A Three-Arm, Pharmacokinetic Study
Kimberly K. Scarsi, Yoninah S Cramer, Susan L. Rosenkranz, Francesca T. Aweeka, Baiba Berzins
The Lancet. HIV. 2019-09-01
63 citations
HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers
Radwa Sharaf, Guinevere Q. Lee, Xiaoming Sun, Behzad Etemad, Layla M. Aboukhater
The Journal of Clinical Investigation. 2018-08-31

Journal Articles

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases

Grant Support

HIV-1, Exercise And Endothelial FunctionNational Heart, Lung, And Blood Institute2011
CTL Exclusion From Lymphoid Follicles As A Mechanism Of Lentivirus Immune InvasioNational Institute Of Allergy And Infectious Diseases2010
Sex Differences In Plasma HIV-1 RNA ConcentrationsEunice Kennedy Shriver National Institute Of Child Health &Human Development2006–2010
Immunology CoreNational Institute Of Allergy And Infectious Diseases2008
Trtmnt Intruptn Amng Sbjts On Potent Antirtroviral Thrpy W/In 16 Dys Of DiagnssNational Center For Research Resources2007–2008
Trtmnt W/Tenofovir Df,Emtricitabine,&Lopinavir/Ritonavir VS NO Therapy In HIVNational Center For Research Resources2006–2008
Trtmnt W/Lamivudine+Stavudine+Abacavir+Amprenavir/Ritonavir W/Supv InterruptionNational Center For Research Resources2005–2008
Acute HIV Infection And Early Disease Research Program (AIEDRP) Core01 Data ProtNational Center For Research Resources2005–2008
ACTG A5201(V 20)-Regmin Smplfctn To Atazanavir/Ritonavir Aftr Vrlgc SuppressionNational Center For Research Resources2005–2008
Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2004–2007
Immune Reconstitution W/Growth Hormin HIV Subjw/Incompcd4+Lymphreston HaartNational Center For Research Resources2005
ACTG A5015-Immunologic &Virologic Indices Assoc W/ Aging In Hiv-Infected SubjecNational Center For Research Resources2005
Tx W/ Lamivudine+Stavudine+Abacavir+Amprenavir+RitonavirNational Center For Research Resources2004
Immune Reconstitution W/ Growth Hormone In HIVNational Center For Research Resources2004
Evaluate Ability Of Vaccine-Induced Helper &CtlNational Center For Research Resources2004
ACTG A5136-Immune Effect Of Antiretroviral Tx IntensityNational Center For Research Resources2004
ACTG A5015-Immunologic &Virologic Indices Assoc W/AgingNational Center For Research Resources2004
Cd8+Tcell Antiretroviral Mechanisms In Lymphoid TissueNational Institute Of Allergy And Infectious Diseases2003
ACTG 375 Immunologic &Virologic Consequences--Long Term Haart In HIV-1 DISENational Center For Research Resources1999–2002
Costimulatory Molecules, CTL, And HIV In Lymphoid TissueNational Institute Of Allergy And Infectious Diseases1998–2002
Actg328 Recombinant Human Interleukin 2--Iv Or Subcutaneous AdministrationNational Center For Research Resources1998–2002
Autologous Cd4-Zeta Gene-Modified T Cells In HIV Infected PatientsNational Center For Research Resources1997–2000
Study Of Safety Of Interleukin-12 In HIV Infected PatientsNational Center For Research Resources1997
Lymphopheresis To Determine Yield, Transducility And Growth Of CD8+ CellsNational Center For Research Resources1997
Study Of Lymphopheresis To Determine Yield, Transducility And GrowthNational Center For Research Resources1996
Rhil12 For HIV Subjects With 100 300 CD4 Cells/Mm3 Of BloodNational Center For Research Resources1996